CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q3 2025 FINANCIAL RESULTS & COMPANY UPDATE
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q3 2025 FINANCIAL RESULTS & COMPANY UPDATE CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q3 2025 FINANCIAL RESULTS & COMPANY UPDATE PR Newswire NASHVILLE, Tenn., Oct...
PR Newswire·15d ago
CUMBERLAND PHARMACEUTICALS' VIBATIV ADDED TO NATIONAL GROUP PURCHASING AGREEMENT WITH PREMIER, INC.
CUMBERLAND PHARMACEUTICALS' VIBATIV ADDED TO NATIONAL GROUP PURCHASING AGREEMENT WITH PREMIER, INC. CUMBERLAND PHARMACEUTICALS' VIBATIV ADDED TO NATIONAL GROUP PURCHASING AGREEMENT WITH PREMIER, INC...
PR Newswire·30d ago
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS
VIBATIV RECEIVES MARKETING APPROVAL IN CHINA VIBATIV RECEIVES MARKETING APPROVAL IN CHINA PR Newswire NASHVILLE, Tenn. and SHANGHAI, Feb. 18, 2025 Vibativ is a life-saving antibiotic for pneumonia...
PR Newswire·9mo ago
Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease
Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease Cumberland Pharmaceuticals Announces Breakthrough Results from...
PR Newswire·9mo ago
Cumberland Pharma Stock Hits 16-Month High After FDA Approves Liver Drug Regimen: Retail’s Thrilled
The newly approved regimen combines the first two standard doses into a single, slower infusion, simplifying administration and improving patient outcomes, according to experts.
Stocktwits·11mo ago
FDA APPROVES ACETADOTE sNDA
FDA APPROVES ACETADOTE sNDA FDA APPROVES ACETADOTE sNDA PR Newswire NASHVILLE, Tenn., Dec. 9, 2024 - New Dosing Regimen Simplifies Administration - NASHVILLE, Tenn., Dec. 9, 2024 /PRNewswire...
PR Newswire·11mo ago
Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update
Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update PR Newswire...
PR Newswire·1y ago
CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND...